Talk:Visfatin

Untitled
This is now being linked to type 2 diabetes, not just as a marker but as a pathogenetic contributor. I can't access Arner's commentary. JFW | T@lk  17:49, 11 January 2006 (UTC)


 * Wollf, you can download it as a PDF file. A change in the concentration of something most of the time is the result of a pathological process not the cause, and i'm pretty sure you know that. In the case of visfatin, the increased plasma concentration could be the result of the body's attempts to cope with the incresed Glc concentration, by using an emergancy redundant system - visfatin can bind to the very same insulin receptor. The authors have found a correlation between the plasma concentration of visfatin and T2DM but at the end of the material they have clearly said that - "In conclusion, our results of elevated visfatin in uncomplicated type 2 diabetic subjects indicate that visfatin MAY play a role in the pathogenesis of T2DM." - which is not the same as stating that visfatin is a pathogenic contributor. -- Boris 20:49, 11 January 2006 (UTC)

I used the term "being linked", which I thought was tentative enough. And the multivariate analysis certainly strengthens the point that visfatin is more than just a marker. JFW | T@lk  21:21, 12 January 2006 (UTC)

Nampt/PBEF/visfatin
I have updated the entry about Visfatin to more accurately summarize the knowledge behind this fascinating protein. There is a lot of confusion about the enzymatic activity of visfatin, partly because the authors that re-identified it neglected to mention that it is a well-established enzyme. For more updates on Nampt, PBEF, or visfatin, please visit "Pubmed.com". Most of these scientific articles are now available to the public for free.--Jrevollo 02:24, 15 November 2006 (UTC)

NAD?
Is NAD Nicotinamide adenine dinucleotide? RJFJR (talk) 15:07, 13 October 2009 (UTC)